Supplemental Balance Sheet Information

6 Months Ended

Mar. 31, 2023

Balance Sheet Related Disclosures [Abstract]

5. Supplemental Balance Sheet Information

Inventories

Inventories consisted of the following components:


	March 31,		September 30,
(In thousands)	2023		2022
Raw materials	$	8,262	$	6,102
Work-in process		2,083		1,595
Finished products		3,422		4,122
Total	$	13,767	$	11,819

Prepaids and Other Assets, Current

Prepaids and other current assets consisted of the following:


	March 31,		September 30,
(In thousands)	2023		2022
Prepaid expenses	$	4,034	$	2,570
Irish research and development credits receivable		836		753
CARES Act employee retention credit receivable (1)		3,441		3,441
Prepaids and other	$	8,311	$	6,764

(1)

Receivable consisted of anticipated reimbursement of personnel expenses incurred in fiscal periods prior to fiscal 2023 as a result of our eligibility for the employee retention credit under the provisions of the Coronavirus Aid, Relief and Economic Security Act (the “CARES Act”).

Intangible Assets

Intangible assets consisted of the following:


	March 31, 2023
(Dollars in thousands)	Weighted Average Original Life (Years)		Gross Carrying Amount		Accumulated Amortization			Net
Definite-lived intangible assets:
Customer lists and relationships		8.9	$	12,476	$	(10,160	)	$	2,316
Developed technology		11.9		34,708		(9,883	)		24,825
Patents and other		14.1		3,551		(2,546	)		1,005
Total definite-lived intangible assets				50,735		(22,589	)		28,146
Unamortized intangible assets:
Trademarks and trade names				580		—			580
Total intangible assets			$	51,315	$	(22,589	)	$	28,726


	September 30, 2022
(Dollars in thousands)	Weighted Average Original Life (Years)		Gross Carrying Amount		Accumulated Amortization			Net
Definite-lived intangible assets:
Customer lists and relationships		8.9	$	11,354	$	(8,827	)	$	2,527
Developed technology		11.9		31,943		(7,994	)		23,949
Patents and other		14.1		3,551		(2,462	)		1,089
Total definite-lived intangible assets				46,848		(19,283	)		27,565
Unamortized intangible assets:
Trademarks and trade names				580		—			580
Total intangible assets			$	47,428	$	(19,283	)	$	28,145

Intangible asset amortization expense was $0.9 million and $1.1 million for the three months ended March 31, 2023 and 2022, respectively, and $1.9 million and $2.3 million for the six months ended March 31, 2023 and 2022, respectively. Based on the intangible assets in service as of March 31, 2023, estimated amortization expense for future fiscal years was as follows:


(In thousands)
Remainder of 2023	$	1,888
2024		3,777
2025		3,741
2026		2,844
2027		2,593
2028		2,582
Thereafter		10,721
Definite-lived intangible assets	$	28,146

Future amortization amounts presented above are estimates. Actual future amortization expense may be different as a result of future acquisitions, impairments, changes in amortization periods, foreign currency translation rates, or other factors.

Goodwill

Changes in the carrying amount of goodwill by segment were as follows:


(In thousands)	In Vitro Diagnostics		Medical Device		Total
Goodwill as of September 30, 2022	$	8,010	$	32,700	$	40,710
Currency translation adjustment		—		3,113		3,113
Goodwill as of March 31, 2023	$	8,010	$	35,813	$	43,823

Other Assets, Noncurrent

Other noncurrent assets consisted of the following:


	March 31,		September 30,
(In thousands)	2023		2022
Operating lease right-of-use assets	$	3,319	$	3,633
Other		1,437		1,136
Other assets	$	4,756	$	4,769

Other noncurrent assets consisted primarily of prepaid expenses and receivables related to refundable Irish research and development tax credits.

Accrued Other Liabilities

Accrued other liabilities consisted of the following:


	March 31,		September 30,
(In thousands)	2023		2022
Accrued professional fees	$	413	$	279
Accrued clinical study expense		1,896		1,425
Accrued purchases		1,297		1,655
Acquisition of in-process research and development (1)		967		981
Income tax payable		36		—
Restructuring (2)		308		—
Operating lease liability, current portion		1,044		963
Other		502		551
Total accrued other liabilities	$	6,463	$	5,854

(1)

Acquisition of in-process research and development consisted of the present value of guaranteed payments to be made (current portion) in connection with an asset acquisition in fiscal 2018 (Note 11).

(2)

Restructuring consisted of accrued severance and related expenses associated with a workforce restructuring initiated in the second quarter of fiscal 2023 (Note 12).

Other Long-term Liabilities

Other long-term liabilities consisted of the following:


	March 31,		September 30,
(In thousands)	2023		2022
Deferred consideration (1)	$	3,404	$	4,260
Contingent consideration (2)		835		829
Unrecognized tax benefits (3)		1,997		1,841
Operating lease liabilities (4)		3,317		3,843
Other		189		—
Other long-term liabilities	$	9,742	$	10,773

(1)

Deferred consideration consisted of the present value of guaranteed payments to be made (noncurrent portion) in connection with the fiscal 2021 Vetex acquisition and with an asset acquisition in fiscal 2018 (Note 11).

(2)

Contingent consideration consisted of the fair value of contingent consideration liabilities associated with the fiscal 2021 Vetex acquisition (Note 11).

(3)

Balance of unrecognized tax benefits (Note 10) includes accrued interest and penalties, if applicable.

(4)

Operating lease liabilities consisted of the non-current portion of the net present value of future minimum lease payments, reduced by the discounted value of leasehold improvement incentives paid or payable to the Company.